Search
forLearn
5 / 801 resultslearn AC Retinol Liposome
learn enoxolone
learn Ethynylestradiol
learn TeraBond™ (Actera)
Research
5 / 1000+ results
research Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials
Extended-release divalproex is better tolerated and more effective for seizures and psychiatric symptoms than delayed-release divalproex, but doesn't reduce hair loss.
research A 6-month prospective study on efficacy safety and QOL profiles of extended-release formulation of valproate in patients with epilepsy
Extended-release valproate effectively reduced seizures and improved quality of life in epilepsy patients over 6 months, with some side effects.
research Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium
Switching to extended-release divalproex sodium improved patient-reported tremor but did not change seizure frequency or most side effects.
research Three months extended-release microspheres prepared by multi-microchannel microfluidics in beagle dog models
A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
research The Extended Centrolateral Endoscopic Midface Lift
The technique improves facial aging signs with a low risk of complications and a recovery time of about 3 weeks.
Community Join
5 / 196 resultscommunity 30 new hair per cm by extended release minoxidil
Extended-release minoxidil shows promise for hair regrowth, potentially adding 30 new hairs per cm, but concerns about side effects like increased body hair and shortness of breath remain. Users discuss combining it with finasteride or dutasteride for better results, while some express skepticism about it being a complete cure.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.
community I’m taking Veradermics VDPHL01 - AMA
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.